- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04248283
Justerbar kontinensterapi (ACT) til behandling af kvindelig SUI
En klinisk undersøgelse af justerbar kontinensterapi (ACT) for kvindelig stress-urininkontinens på grund af intrinsic sphincter deficiency
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Lisa Draper
- Telefonnummer: 612-834-7494
- E-mail: USLDR@COLOPLAST.COM
Undersøgelse Kontakt Backup
- Navn: Matt Kelly, PhD
- Telefonnummer: 612-469-8882
- E-mail: usmtk@coloplast.com
Studiesteder
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80045
- Rekruttering
- University of Colorado
-
Kontakt:
- Andrea Pina
- E-mail: andrea.pinalimones@cuanschutz.edu
-
Ledende efterforsker:
- Brian Flynn, MD
-
-
Idaho
-
Meridian, Idaho, Forenede Stater, 83642
- Rekruttering
- Idaho Urologic Institute, PA
-
Kontakt:
- Karrie Fox
- E-mail: karried@idurolog.com
-
Kontakt:
- Brian Mihm
- E-mail: bmihm@idurology.com
-
Ledende efterforsker:
- Lisa Parillo, MD
-
-
Missouri
-
Independence, Missouri, Forenede Stater, 64055
- Aktiv, ikke rekrutterende
- Saint Lukes Health System
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68124
- Rekruttering
- CHI Health Research Center
-
Ledende efterforsker:
- Michael Feloney, MD
-
Kontakt:
- Jodi Salvatori, RN, BSN
- Telefonnummer: 402-343-8511
- E-mail: jodi.salvatori@commonspirit.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Rekruttering
- Penn State University
-
Kontakt:
- Jocelyn Chavla
- E-mail: jchavla@pennstatehealth.psu.edu
-
Ledende efterforsker:
- Arturo Garcia Mora, MD
-
-
-
-
-
Marseille, Frankrig, 13005
- Rekruttering
- Hôpital de la Conception - Marseille
-
Kontakt:
- Nassima Rabah
- Telefonnummer: +33 (0)4 91 38 11 34
- E-mail: nassima.rabah@ap-hm.fr
-
Ledende efterforsker:
- Gilles Karsenty, MD
-
Nantes, Frankrig, 44000
- Rekruttering
- CHU de Nantes
-
Kontakt:
- Amanda Simon
- Telefonnummer: +33 2 40 08 39 10
- E-mail: amanda.simon@chu-nantes.fr
-
Ledende efterforsker:
- Marie-Aimee Perrouin-Verbe, MD
-
Paris, Frankrig, 75013
- Rekruttering
- Pitié Salpêtrière University Hospital Paris
-
Kontakt:
- Kamilia Zedek
- Telefonnummer: +33 (01) 84 82 83 23
- E-mail: kamilia.zedek@aphp.fr
-
Ledende efterforsker:
- Emmanuel Chartier-Kastler, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Female at least 22 years old
- Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
- Provocative pad weight of greater than 11.0 grams
- Candidate for surgical intervention
- Negative urinalysis
- Normal cystourethroscopy
- Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)
- Willing and able to sign informed consent and comply with trial follow-up requirements
Exclusion Criteria:
- Pregnant or lactating
- Life expectancy of less than 5 years
- Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL
- Has auto-immune disease
- Undergoing radiation therapy
- Active urinary tract infection
- Detrusor instability refractory to medication
- Reduced bladder compliance as defined by a cystometrogram
- Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml
- Has, had, or is suspected of having bladder cancer
- History of bladder stones
- Urethral stricture evidenced during cystourethroscopy
- Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
- Has a diathesis, hemophilia, or a bleeding disorder
- Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher
- Had prior pelvic radiotherapy
- Had a prior artificial urinary sphincter implanted
- Has a neurogenic condition known to affect bladder/sphincter function
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Adjustable Continence Therapy for Women
Implantation of the Adjustable Continence Therapy for the treatment of female SUI. |
Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately). |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Provocative pad weight
Tidsramme: 12 months
|
Change in provocative pad weight from baseline |
12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Urogenital Distress Inventory (UDI)
Tidsramme: 12 months
|
Six item questionnaire. Scores range from 0-100. 0 being not distressed, 100 being very distressed. |
12 months
|
|
Incontinence Quality of Life Questionnaire (I-QOL)
Tidsramme: 12 months
|
Twenty-two item questionnaire. Scores range from 0-100. 0 being lowest quality of life, 100 being highest quality of life. |
12 months
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete adverse event profile
Tidsramme: 12 months
|
Collection of patient safety information |
12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Philip Johnson, PhD, Uromedica, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Psykiske lidelser
- Mandlige urogenitale sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Urologiske manifestationer
- Adfærdsmæssige symptomer
- Eliminationsforstyrrelser
- Patologiske tilstande, tegn og symptomer
- Opførsel
- Tegn og symptomer
- Enuresis
- Ufrivillig vandladning
- Urininkontinens, stress
- Urologiske sygdomme
- Nedre urinvejssymptomer
- Natlig enurese
- Vandladningsforstyrrelser
Andre undersøgelses-id-numre
- UM08
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .